Opening https://www.businesswire.com/news/home/20230322005380/en/Alzamend-Neuro-Announces-Completion-of-Clinical-Portion-of-Phase-IIA-Multiple-Ascending-Dose-Clinical-Trial-for-AL001-Treatment-of-Dementia-Related-to-Alzheimer%E2%80%99s